Francesca Palandri

Summary

Country: Italy

Publications

  1. ncbi request reprint Long-term molecular responses to imatinib in patients with chronic myeloid leukemia: comparison between complete cytogenetic responders treated in early and in late chronic phase
    Francesca Palandri
    Haematologica 92:1579-80. 2007
  2. pmc The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase
    Francesca Palandri
    Department of Hematology Oncology L and A Seràgnoli, University of Bologna, S Orsola Malpighi Hospital, Bologna, Italy
    Haematologica 95:1415-9. 2010
  3. doi request reprint Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge.
    Francesca Palandri
    Institute of Hematology L and A Ser gnoli, St Orsola Malpighi Hospital, Department of Specialistic, Diagnostic and Experimental Medicine, University of Bologna, Via Massarenti 9, 40138, Bologna, Italy
    Ann Hematol 94:519-20. 2015
  4. doi request reprint Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience.
    Francesca Palandri
    Department of Hematology Oncology, L and A Seragnoli, St Orsola Malpighi University Hospital, Bologna, Italy
    Leuk Lymphoma 50:481-4. 2009
  5. pmc Romiplostim as early treatment of immune thrombocytopenia with severe immunodeficiency
    Francesca Palandri
    Department of Hematology and Oncology L e A Seragnoli, St Orsola Malpighi Hospital, University of Bologna
    Hematol Rep 4:e10. 2012
  6. pmc Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure
    Francesca Palandri
    Department of Hematology and Medical Oncology L and A Seràgnoli, St Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Haematologica 94:1758-61. 2009
  7. doi request reprint Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML
    Francesca Palandri
    Department of Hematology Oncology L and A Seràgnoli S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    J Clin Oncol 26:106-11. 2008
  8. doi request reprint Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome
    Francesca Palandri
    Department of Hematology and Oncology L and A Seràgnoli, St Orsola Malpighi University Hospital, Via Massarenti 9, 40138 Bologna, Italy
    Haematologica 93:770-4. 2008
  9. doi request reprint Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party
    Fausto Castagnetti
    Institute of Hematology L and A Seràgnoli, University of Bologna, Bologna, Italy
    Blood 113:3428-34. 2009
  10. ncbi request reprint Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis
    Simona Luatti
    Department of Hematology and Oncology L e A Seragnoli, University of Bologna, Bologna, Italy
    Blood 120:761-7. 2012

Detail Information

Publications50

  1. ncbi request reprint Long-term molecular responses to imatinib in patients with chronic myeloid leukemia: comparison between complete cytogenetic responders treated in early and in late chronic phase
    Francesca Palandri
    Haematologica 92:1579-80. 2007
    ..ECP patients obtained earlier, higher and more sustained MMolR...
  2. pmc The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase
    Francesca Palandri
    Department of Hematology Oncology L and A Seràgnoli, University of Bologna, S Orsola Malpighi Hospital, Bologna, Italy
    Haematologica 95:1415-9. 2010
    ..78%; P=0.02). These data suggest that the response to the combination treatment is more rapid. It is not yet known how much a rapid reduction will influence the longer-term overall and progression free survival, and the cure rate...
  3. doi request reprint Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge.
    Francesca Palandri
    Institute of Hematology L and A Ser gnoli, St Orsola Malpighi Hospital, Department of Specialistic, Diagnostic and Experimental Medicine, University of Bologna, Via Massarenti 9, 40138, Bologna, Italy
    Ann Hematol 94:519-20. 2015
  4. doi request reprint Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience.
    Francesca Palandri
    Department of Hematology Oncology, L and A Seragnoli, St Orsola Malpighi University Hospital, Bologna, Italy
    Leuk Lymphoma 50:481-4. 2009
  5. pmc Romiplostim as early treatment of immune thrombocytopenia with severe immunodeficiency
    Francesca Palandri
    Department of Hematology and Oncology L e A Seragnoli, St Orsola Malpighi Hospital, University of Bologna
    Hematol Rep 4:e10. 2012
    ..The present experience supports the effectiveness and safety of TRAs as early treatment of ITP patients with drug-induced immunodeficiency or with active infections...
  6. pmc Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure
    Francesca Palandri
    Department of Hematology and Medical Oncology L and A Seràgnoli, St Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Haematologica 94:1758-61. 2009
    ..The mechanisms of action of nilotinib on pancreatic enzymes deserves to be investigated: however, in our experience, the relevance of pancreatic hyperenzymemia was clinically very limited...
  7. doi request reprint Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML
    Francesca Palandri
    Department of Hematology Oncology L and A Seràgnoli S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    J Clin Oncol 26:106-11. 2008
    ..Imatinib mesylate (IM) has rapidly become the front-line treatment of Philadelphia-positive (Ph-pos) chronic myeloid leukemia, but the number of patients who were treated and are being treated with IM second-line is still substantial...
  8. doi request reprint Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome
    Francesca Palandri
    Department of Hematology and Oncology L and A Seràgnoli, St Orsola Malpighi University Hospital, Via Massarenti 9, 40138 Bologna, Italy
    Haematologica 93:770-4. 2008
    ..Any possible additional benefit of the combination with interferon-alpha remains uncertain, due to low patient compliance...
  9. doi request reprint Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party
    Fausto Castagnetti
    Institute of Hematology L and A Seràgnoli, University of Bologna, Bologna, Italy
    Blood 113:3428-34. 2009
    ..These clinical trials are registered at www.clinicaltrials.gov as no. NCT00510926...
  10. ncbi request reprint Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis
    Simona Luatti
    Department of Hematology and Oncology L e A Seragnoli, University of Bologna, Bologna, Italy
    Blood 120:761-7. 2012
    ..The prognostic significance of each specific cytogenetic abnormality was not assessable. Therefore, we confirm that ACAs constitute an adverse prognostic factor in CML patients treated with imatinib as frontline therapy...
  11. doi request reprint Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis
    Fausto Castagnetti
    Department of Hematology and Oncological Sciences, Sant Orsola Malpighi Hospital, University of Bologna, Via Massarenti 9, Bologna, Italy
    J Clin Oncol 28:2748-54. 2010
    ..For this reason, in 2006, the European LeukemiaNet recommendations still considered der(9) deletions as a candidate adverse prognostic factor and required a careful monitoring of the patient...
  12. doi request reprint Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response
    Francesca Palandri
    Department of Hematology Oncology L and A Seràgnoli, St Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Clin Cancer Res 15:1059-63. 2009
    ..The achievement of a major molecular response (MMolR) at 12 months is a surrogate marker of progression-free survival in chronic myeloid leukemia patients treated with imatinib...
  13. doi request reprint Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors
    Simona Soverini
    Department of Hematology and Oncological Sciences L e A Seràgnoli, University of Bologna, Bologna, Italy
    Blood 114:2168-71. 2009
    ....
  14. doi request reprint Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party
    Gabriele Gugliotta
    Department of Hematology and Oncology Seràgnoli, University of Bologna S Orsola Malpighi Hospital, Bologna, Italy
    Blood 117:5591-9. 2011
    ..These data show that response to IM was not affected by age and that the mortality rate linked to CML is similar in both age groups. This trial was registered at www.clinicaltrials.gov as #NCT00514488 and #NCT00510926...
  15. doi request reprint Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison'
    Gianantonio Rosti
    Department of Hematology and Oncology L e A Seragnoli, S Orsola Malpighi University Hospital, 9 40138 Bologna, Italy
    Leuk Lymphoma 51:583-91. 2010
    ..This consideration involves the differences in both the imatinib-resistant and -intolerant patients enrolled in the pivotal studies for each agent, as well as other trial criteria...
  16. pmc The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up
    Francesca Palandri
    Department of Hematology Oncology L and A Seràgnoli S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Haematologica 94:205-12. 2009
    ..The advent of imatinib increased survival significantly in patients in an advanced phase of the disease. However, few long-term data on the outcome of these patients based on large, prospective and controlled trials are available...
  17. doi request reprint Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up
    Francesca Palandri
    Institute of Hematology and Medical Oncology L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Haematologica 93:1792-6. 2008
    ..In patients with advanced phase of the disease, the advent of imatinib significantly increased survival. However, few long-term data, based on large, prospective and controlled trials are available on the outcome of these patients...
  18. doi request reprint Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib
    Simona Soverini
    Department of Hematology Oncology, University of Bologna and S Orsola Malpighi Hospital, Bologna, Italy
    Leuk Res 35:1527-9. 2011
    ..Our results suggest that a) Bcr-Abl mutations, even at low level, seem to be very rare in patients in MMR on first-line nilotinib; b) low-level mutations do not always predict for subsequent relapse...
  19. doi request reprint JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients
    Francesca Palandri
    Department of Hematology and Clinical Oncology L and A Seràgnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Leuk Lymphoma 50:247-53. 2009
    ..Incidence of thrombosis and disease evolution was comparable. JAK2 mutational status assessment was valuable to distinguish two populations of patients with ET, showing distinctive hematologic and clinical features...
  20. doi request reprint Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study
    Michele Baccarani
    Department of Hematology Oncology L and A Seràgnoli, S Orsola Malpighi University Hospital, Bologna, Italy
    Blood 113:4497-504. 2009
    ..This study does not support the extensive use of high-dose IM (800 mg daily) front-line in all CML HR patients. This trial was registered at www.clinicaltrials.gov as #NCT00514488...
  21. doi request reprint Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis
    Giulia Marzocchi
    Department of Hematology and Oncology L e A Seragnoli, University of Bologna, Bologna, Italy
    Blood 117:6793-800. 2011
    ..Therefore, we suggest that patients with variant translocations do not constitute a "warning" category in the imatinib era. This study is registered at www.clinicaltrials.gov as NCT00514488 and NCT00510926...
  22. pmc Circulating Calreticulin Is Increased in Myelofibrosis: Correlation with Interleukin-6 Plasma Levels, Bone Marrow Fibrosis, and Splenomegaly
    Daria Sollazzo
    Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology L and A Seràgnoli, University of Bologna, Bologna, Italy
    Mediators Inflamm 2016:5860657. 2016
    ..These results demonstrate that the circulating CRT takes part in the inflammatory network of MF and correlates with aggressiveness of the disease...
  23. ncbi request reprint Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party
    Gianantonio Rosti
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy
    Haematologica 92:101-5. 2007
    ..As might be expected, older patients experienced more adverse events, both hematologic and non-hematologic: this worsened compliance did not, however, prevent a long-term outcome similar to that of younger patients...
  24. ncbi request reprint Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain
    Simona Soverini
    Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, Bologna, Italy
    Haematologica 92:401-4. 2007
    ..In all patients but one, resistance to dasatinib was invariably found to be associated with mutations at residue 315 and/or at residue 317...
  25. doi request reprint Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis
    Marco Romano
    Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology L e A Seràgnoli, University of Bologna, Bologna, Italy
    Oncoimmunology 6:e1345402. 2017
    ..Overall, we have demonstrated that in MF different mutations lead to phenotypic and functional alterations in different immune subsets that may have a potential role in disease progression and susceptibility to infections...
  26. doi request reprint Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy
    Francesca Palandri
    Department of Hematology and Medical Oncology L e A Seràgnoli, St Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Am J Hematol 84:215-20. 2009
    ....
  27. doi request reprint Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study
    Francesca Palandri
    Department of Hematology and Oncology L e A Seragnoli, St Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Ann Hematol 90:933-8. 2011
    ..Baseline leukocytosis correlated with a higher thrombotic risk in high-risk patients and identified a cohort of patients with worse survival...
  28. doi request reprint Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia
    Gianantonio Rosti
    Department of Hematology Oncology, L and A Seragnoli, University of Bologna, S Orsola Malpighi Hospital, 40138 Bologna, Italy
    Blood 114:4933-8. 2009
    ..Nilotinib is safe and very active in early chronic-phase CML. These data support a role for nilotinib for the frontline treatment of CML. This study was registered at ClinicalTrials.gov as NCT00481052...
  29. doi request reprint Response definitions and European Leukemianet Management recommendations
    Michele Baccarani
    Department of Hematology Oncology L and A Seràgnoli, S Orsola Malpighi University Hospital, University of Bologna, Via Massarenti 9, 40138, Bologna, Italy
    Best Pract Res Clin Haematol 22:331-41. 2009
    ..A provisional definition of the response to second-generation TKIs second line is provided...
  30. doi request reprint Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study
    Francesca Palandri
    Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology L and A Seràgnoli, University of Bologna, S Orsola Malpighi Hospital, Bologna, Italy
    Hematol Oncol . 2017
    ..These data support the need for standardized guidelines that may guide the decision to initiate ruxolitinib therapy in this risk category, balancing benefit expectations and potential adverse effects...
  31. doi request reprint The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study
    Margherita Perricone
    Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology L and A Seràgnoli, University of Bologna, S Orsola Malpighi Hospital, Bologna, Italy
    Oncotarget 8:37239-37249. 2017
    ..Remarkably, our data suggest that a cut-off of AB ≥ 0.8% is very indicative for the presence of a MPN. Monitoring of the AB over time emerged as a convenient and non-invasive method to assess clonal hematopoiesis expansion...
  32. pmc Crucial factors of the inflammatory microenvironment (IL-1β/TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study
    Daria Sollazzo
    Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology L e A Seràgnoli, University of Bologna, Bologna, Italy
    Oncotarget 7:43974-43988. 2016
    ..Targeting these micro-environmental interactions may be a clinically relevant approach...
  33. doi request reprint Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain
    Simona Soverini
    Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology L e A Seràgnoli, University of Bologna, Bologna, Italy
    Blood 122:1634-48. 2013
    ..Further evaluation of the clinical usefulness of UDS-based approaches is warranted. ..
  34. doi request reprint Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia
    Lucia Catani
    Institute of Hematology, Department of Hematology and Oncological Sciences L e A Seràgnoli, University of Bologna, Bologna, Italy
    Ann Hematol 92:67-78. 2013
    ..In conclusion, these data point out the role of IDO1 in the impaired regulatory T cell development of ITP patients and suggest that the cross-talk between Tregs and DCs is hampered and plays a pathogenetic role...
  35. doi request reprint Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase
    Gianantonio Rosti
    Department of Hematology and Oncology L and A Seràgnoli, University of Bologna, Italy
    Crit Rev Oncol Hematol 82:159-70. 2012
    ..Clinicians now have several effective options to treat patients newly diagnosed with CML-CP and available data suggest that dasatinib and nilotinib represent improved therapeutic options compared with imatinib...
  36. doi request reprint Physician's guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML
    Gianantonio Rosti
    Department of Hematology and Oncology, L and A Seragnoli, St Orsola University Hospital, University of Bologna, 9 40138 Bologna, Italy
    Cancer Treat Rev 38:241-8. 2012
    ..The objectives of this article are to review the clinical management of the most frequent of these adverse events and to guide physicians in helping their patients maintain adherence and achieve optimal outcomes with nilotinib therapy...
  37. pmc Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance
    Giovanni Martinelli
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy
    Biologics 1:121-7. 2007
    ..Preliminary studies demonstrated that nilotinib has more efficacy than imatinib in inhibiting proliferation of BCR-ABL-dependent cells, a relatively safety profile and clinical efficacy in all phases of CML...
  38. doi request reprint Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis
    Francesca Palandri
    Institute of Hematology L and A Seràgnoli, Sant Orsola Malpighi University Hospital, Bologna, Italy
    Oncotarget 8:79073-79086. 2017
    ..001). Increased disease severity, a delay in RUX start and titrated doses <10 mg BID were associated with patients achievinglower response rates. An early treatment and higher RUX doses may achieve better therapeutic results...
  39. doi request reprint Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years
    Francesca Palandri
    Institute of Hematology L e A Seràgnoli, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Italy
    Am J Hematol 91:E267-72. 2016
    ..3% (1980-89) vs. 7% (1990-99) vs. 5.6% (2000-09) vs. 0.2% (2010-15)] (P < 0.001), mainly thanks to the optimization of front-line corticosteroids therapy and to the wider availability of second and third-line therapies...
  40. doi request reprint Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients
    Nicola Polverelli
    Department of Experimental, Diagnostic and Specialty Medicine DIMES, Institute of Hematology and Clinical Oncology L and A Seràgnoli, Sant Orsola Malpighi University Hospital, Bologna, Italy
    Am J Hematol 92:37-41. 2017
    ..Am. J. Hematol. 92:37-41, 2017. © 2016 Wiley Periodicals, Inc...
  41. doi request reprint The choice of second-line therapy in steroid-resistant immune thrombocytopenia: role of platelet kinetics in a single-centre long-term study
    Francesca Palandri
    Institute of Hematology L and A Seràgnoli, Department of Experimental, Diagnostic and Specialty Medicine, St Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Am J Hematol 89:1047-50. 2014
    ..However, it should be enphasized that the response rate and duration of response even in patients with nonsplenic uptake were similar or even superior to those reported in patients treated with rituximab as first option...
  42. doi request reprint Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia
    Michele Baccarani
    Department of Hematology and Oncology L and A Seràgnoli, Bologna, Italy
    Expert Rev Hematol 7:397-406. 2014
    ..Resistance to imatinib calls without exceptions for a second-generation TKI. In case of resistance to two TKIs, an allogeneic stem cell transplantation should be considered. ..
  43. pmc Imatinib in chronic myeloid leukemia elderly patients
    Gabriele Gugliotta
    Department of Hematology and Clinical Oncology Seràgnoli, S Orsola Malpighi Hospital, University of Bologna, Italy
    Aging (Albany NY) 3:1125-6. 2011
    ..Although data on dasatinib and nilotinib in elderly patients are still few and the follow-up is still short, these second generation tyrosine kinase inhibitors will probably further improve the outcome of CML elderly patients...
  44. doi request reprint The CD47 pathway is deregulated in human immune thrombocytopenia
    Lucia Catani
    Department of Hematology and Oncological Sciences L and A Seràgnoli, Institute of Hematology, University of Bologna, Bologna, Italy
    Exp Hematol 39:486-94. 2011
    ..In this study, we evaluated if the CD47/SIRPα axis may be involved in the apoptosis and clearance of platelets in human ITP...
  45. pmc Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years
    Nicola Vianelli
    Department of Hematology and Clinical Oncology L and A Seràgnoli, University of Bologna, S Orsola Malpighi Hospital, Italy
    Haematologica 98:875-80. 2013
    ..0001). Thrombosis developed in 18 patients (8%) and was fatal in 4. Splenectomy achieved a long-term stable response in approximately 60% of cases. Complications mainly affected non-responding patients and were fatal in a minority...
  46. doi request reprint Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories
    Margherita Perricone
    Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology L and A Seràgnoli, University of Bologna, S Orsola Malpighi Hospital, Bologna, Italy
    Oncotarget 8:32608-32617. 2017
    ....
  47. doi request reprint Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response
    Miriam Marangon
    Institute of Hematology L A Seragnoli, University of Bologna, Bologna, Italy
    Eur J Haematol . 2016
    ..e., probability to achieve and maintain response) and to identify biological and clinical predictors of response...
  48. doi request reprint New strategies in myelofibrosis: the evolving paradigm of disease pathogenesis, prognostication and treatment
    Francesca Palandri
    Department of Experimental, Diagnostic and Specialty Medicine DIMES, Institute of Hematology L and A Seràgnoli, Bologna, Italy
    Hematol Oncol . 2016
    ....
  49. ncbi request reprint Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia
    Simona Soverini
    J Clin Oncol 24:e51-2. 2006
  50. ncbi request reprint Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1402, USA
    Blood 110:3540-6. 2007
    ..In summary, nilotinib is highly active and safe in patients with CML-CP after imatinib failure or intolerance. This clinical trial is registered at http://clinicaltrials.gov as ID no. NCT00109707...